Elsevier

Journal of Autoimmunity

Volume 39, Issue 3, September 2012, Pages 234-239
Journal of Autoimmunity

Low levels of vitamin-D are associated with neuropathy and lymphoma among patients with Sjögren’s syndrome

https://doi.org/10.1016/j.jaut.2012.05.018Get rights and content

Abstract

Background/purpose

Primary Sjögren’s syndrome (SS) is a chronic autoimmune disease primarily involving the exocrine glands. The clinical picture of SS ranges from exocrinopathy to systemic disease affecting the lung, kidney, liver, skin, musculockeletal and nervous systems. The morbidity of SS is mainly determined by extraglandular disease and increased prevalence of lymphoma. Environmental and hormonal factors, such as vitamin-D may play a role in the pathogenic process and disease expression. Thus, we aimed to evaluate levels of vitamin-D and their association with manifestations of SS.

Methods

Vitamin-D levels were determined in 176 primary SS patients and 163 matched healthy volunteers utilizing the LIAISON chemiluminescent immunoassays (DiaSorin-Italy). A correlation between vitamin-D levels and clinical and serological manifestations of SS was performed.

Results

Mean vitamin-D levels were comparable between SS patients and control 21.2 ± 9.4 ng/ml and 22.4 ± 10 ng/ml, respectively. Peripheral neuropathy was diagnosed in 23% of SS patients and associated with lower vitamin-D levels (18.6 ± 5.5 ng/ml vs. 22.6±8 ng/ml (p = 0.04)). Lymphoma was diagnosed in 4.3% of SS patients, who had lower levels of vitamin-D (13.2 ± 6.25 ng/ml), compared to SS patients without lymphoma (22 ± 8 ng/ml), (p = 0.03). Other clinical and serological manifestations did not correlate with vitamin-D status.

Conclusions

In this study, low levels of vitamin-D correlated with the presence of peripheral neuropathy and lymphoma among SS patients. The link between vitamin-D and neuropathy or lymphoma was reported in other conditions, and may support a role for vitamin-D in the pathogenesis of these processes. Plausible beneficial effect for vitamin-D supplementation may thus be suggested.

Highlights

► Vitamin-D levels of Sjogren's syn. patients do not differ from the healthy population. ► Peripheral neuropathy was diagnosed in 23% of Sjogren’s syn. patients in this cohort. ► Lymphoma was diagnosed in 4.3% of Sjogren’s syn. patients. ► Peripheral neuropathy and lymphoma were associated with lower vitamin-D levels.

Introduction

Sjögren’s syndrome (SS) is a slowly progressing autoimmune disease affecting the exocrine glands of predominantly middle aged women. This syndrome can present alone as primary SS (pSS) or in the context of underlying connective tissue disease as secondary SS. The prevalence of SS is reported to be between 0.1 and 4.8% depending on different reports from different geographical and ethnical areas [1], [2]. Extra glandular manifestations appear in up to a half of the patients with Sjögren’s syndrome, may involve the joints, skin, lung, central and peripheral nervous system, and may associate with various autoantibody profiles [3]. An increased incidence of lymphoma in SS patients, mainly of B-cell origin, is repeatedly demonstrated in large epidemiological studies [4], [5]. While the etiology of SS is unknown, genetic, environmental, and hormonal factors are considered to play a major role in its pathogenesis [6], [7]. Vitamin-D is a pro-hormone with important impact on bone and mineral homeostasis. During the last two decades vitamin-D has been linked to the development of cardiovascular diseases [8], cancer [9], [10], glucose intolerance [11], and all cause mortality [12]. Some of these conditions are associated with genetic polymorphisms in vitamin-D metabolism-related genes [10]. In addition, vitamin-D has been found to possess immune-regulatory and immune-suppressive effects in vitro and in vivo [13]. At least some of vitamin-D’s immune-modulatory properties are ascribed to its effect on immune cells of the innate and adaptive systems, including macrophages, dendritic cells, and T and B lymphocytic cells, all of which harbor vitamin-D receptors. Noteworthy are DCs, which are a primary target for the immunomodulatoric activity of vitamin-D [14], [15]. Vitamin-D has been shown to inhibit DC-dependent T-cell activation, and promote tolerogenic properties that favor the induction of regulatory rather that effector T-cells. Low vitamin-D levels, and higher prevalence of vitamin-D deficiency are consistently demonstrated in several autoimmune diseases, such as type I diabetes mellitus [16], rheumatoid arthritis [17], [18], autoimmune thyroid diseases [19], [20] mixed connective tissue disease [21], systemic lupus erythematosus [22], [23], [24], the anti-phospholipids syndrome (APS) [25] and systemic sclerosis [26]. Moreover, in several of these autoimmune diseases, vitamin-D levels correlated with disease severity, as well as clinical and serological markers. This could also explain the striking latitude differences found in several autoimmune diseases, which have an inverse correlation with vitamin-D status [27], [28]. Several experiments showed that vitamin-D supplementation can improve disease related symptoms in animal models of autoimmune diseases [29], as well as in patients suffering from AD’s [16], [30], [31], [32].

To date, two small case–control studies have evaluated vitamin-D levels in patients with SS, with inconclusive results. In one, which involved 25 pSS patients and 15 healthy controls from Hungary, vitamin-D levels were similar 79.9 vs. 71.5 nmol/l (p = 0.4), respectively. The authors indicated also, that no significant differences in vitamin-D levels were detected in pSS patients with and without extraglandular manifestations [33]. The second study, conducted in 1990, however, did suggest the presence of an abnormal vitamin-D3 metabolism in pSS patients [34]. In this Danish work, Muller K. and his colleagues demonstrated normal 1, 25-OH D3 levels, but lower 25-OH D3 levels, in 41 pSS patients compared to normal controls. Serum levels of Gc globulin (the main vitamin-D3 binding protein in the blood) and the distribution of its phenotypes did not differ from the normal subjects, as well. In their follow-up article in 1999, which dealt with the same 41 pSS patients, again, 25-OH D3 levels, and not 1, 25-OH D3, inversely correlated with clinical manifestations, and levels of immune-inflammatory markers [35].

In light of the uncertainty regarding the vitamin-D-SS relationship, we conducted a case–control study comparing vitamin-D levels of patients with pSS from several European countries with their matched healthy controls. In addition, we aimed to evaluate the association between vitamin-D concentrations and different manifestations of SS.

Section snippets

Study population

Serum samples were drawn from 176 consecutive pSS patients (including 169 females), treated in several European autoimmune-rheumatic medical centers. All patients were diagnosed with pSS according to the revised international classification criteria for Sjögren’s syndrome [36]. Patients were documented for demographical (age, gender), glandular and extraglandular, clinical (xerostomia, xerophthalmia, salivary gland enlargement, fever, fatigue, fibromyalgia, joint/muscle symptoms,

Vitamin-D levels in patients compared to healthy controls

Vitamin-D levels (mean ± standard deviation) of 176 patients with pSS were comparable to those of 163 healthy controls: 21.2 ± 9.4 vs. 22.4 ± 10 ng/ml, respectively (p = 0.2). In addition, the rate of vitamin-D levels lower than 20 ng/ml or lower than 10 ng/ml were 50% vs. 44.7% (p = 0.29), and 12.5% vs. 11.3% (p = 0.23) among patients and controls, respectively.

Vitamin-D levels and demographic parameters among patients with pSS

Among patients with pSS, there was no significant correlation between vitamin-D levels and gender. Mean vitamin-D levels were 21 ± 8.9

Discussion

According to our results, vitamin-D levels of patients with primary Sjögren’s syndrome are not lower than those measured in the equivalent healthy population. However, lower vitamin-D levels among pSS patients did correlate inversely with older age. This finding is supported by previous studies, including ours, demonstrating decreasing vitamin-D levels with age in patients with other autoimmune diseases such as celiac disease [38] as well as in the healthy general population [39], [40], [41].

Conclusions

In the current study we found that although levels of vitamin-D were comparable between patients with pSS and healthy controls, low levels of this vitamin correlated with peripheral neuropathy and the presence of lymphoma among the pSS patients. These inverse associations have been documented in other conditions thereby suggesting a role for vitamin-D in the process of neuronal damage and lymphoproliferative diseases. These findings may warrant the need for a tighter monitoring of vitamin-D

References (104)

  • A. Arabi et al.

    Age but not gender modulates the relationship between PTH and vitamin D

    Bone

    (2010)
  • S. Skalli et al.

    Vitamin D deficiency and peripheral diabetic neuropathy

    Eur J Intern Med

    (2012)
  • P. Valensi et al.

    A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report

    J Diabetes Complications

    (2005)
  • Y. Peri et al.

    Sjogren’s syndrome, the old and the new

    Best Pract Res Clin Rheumatol

    (2012)
  • F.N. Skopouli et al.

    Clinical evolution, and morbidity and mortality of primary Sjogren’s syndrome

    Semin Arthritis Rheum

    (2000)
  • J. Polesel et al.

    Linoleic acid, vitamin D and other nutrient intakes in the risk of non-Hodgkin lymphoma: an Italian case–control study

    Ann Oncol

    (2006)
  • E.T. Chang et al.

    Adulthood residential ultraviolet radiation, sun sensitivity, dietary vitamin D, and risk of lymphoid malignancies in the California Teachers Study

    Blood

    (2011)
  • M.E. Gershwin et al.

    Chella David: a lifetime contribution in translational immunology

    J Autoimmun

    (2011)
  • N.R. Rose

    The genetics of autoimmune thyroiditis: the first decade

    J Autoimmun

    (2011)
  • P. Youinou et al.

    Moutsopoulos: a lifetime in autoimmunity

    J Autoimmun

    (2010)
  • Y. Arnson et al.

    Effects of tobacco smoke on immunity, inflammation and autoimmunity

    J Autoimmun

    (2010)
  • B. Ranque et al.

    Geoepidemiology of systemic sclerosis

    Autoimmun Rev

    (2010)
  • A. Meyer et al.

    Geoepidemiology of myasthenia gravis [corrected]

    Autoimmun Rev

    (2010)
  • N. Meyer et al.

    Geoepidemiologic considerations of auto-immune pemphigus

    Autoimmun Rev

    (2010)
  • A.T. Borchers et al.

    The geoepidemiology of systemic lupus erythematosus

    Autoimmun Rev

    (2010)
  • K. Hemminki et al.

    The epidemiology of Graves’ disease: evidence of a genetic and an environmental contribution

    J Autoimmun

    (2010)
  • M.H. Hoffmann et al.

    Nucleic acid-associated autoantigens: pathogenic involvement and therapeutic potential

    J Autoimmun

    (2010)
  • A.T. Borchers et al.

    The geoepidemiology of type 1 diabetes

    Autoimmun Rev

    (2010)
  • W.H. Brooks et al.

    Epigenetics and autoimmunity

    J Autoimmun

    (2010)
  • C. Chang et al.

    Drugs and autoimmunity–a contemporary review and mechanistic approach

    J Autoimmun

    (2010)
  • M. Chen et al.

    The complement system in systemic autoimmune disease

    J Autoimmun

    (2010)
  • J.L. Round et al.

    Coordination of tolerogenic immune responses by the commensal microbiota

    J Autoimmun

    (2010)
  • C. Selmi

    The worldwide gradient of autoimmune conditions

    Autoimmun Rev

    (2010)
  • M. Chen et al.

    The environment, geoepidemiology and ANCA-associated vasculitides

    Autoimmun Rev

    (2010)
  • A. Bhat et al.

    The epidemiology of transverse myelitis

    Autoimmun Rev

    (2010)
  • M. Biggioggero et al.

    The geoepidemiology of the antiphospholipid antibody syndrome

    Autoimmun Rev

    (2010)
  • S. Deane et al.

    The geoepidemiology of immune thrombocytopenic purpura

    Autoimmun Rev

    (2010)
  • M. Ehrenfeld

    Geoepidemiology: the environment and spondyloarthropathies

    Autoimmun Rev

    (2010)
  • P. Invernizzi

    Geoepidemiology of autoimmune liver diseases

    J Autoimmun

    (2010)
  • J.F. Lambert et al.

    Geoepidemiology of autoimmune hemolytic anemia

    Autoimmun Rev

    (2010)
  • V. Chandran et al.

    Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis

    J Autoimmun

    (2010)
  • Y. Berkun et al.

    Environmental factors and the geoepidemiology of juvenile idiopathic arthritis

    Autoimmun Rev

    (2010)
  • C. Chang

    The immune effects of naturally occurring and synthetic nanoparticles

    J Autoimmun

    (2010)
  • P.S. Leung et al.

    Development and validation of gene therapies in autoimmune diseases: epidemiology to animal models

    Autoimmun Rev

    (2010)
  • C. Selmi et al.

    Nutrition, geoepidemiology, and autoimmunity

    Autoimmun Rev

    (2010)
  • Y. Shapira et al.

    Defining and analyzing geoepidemiology and human autoimmunity

    J Autoimmun

    (2010)
  • L. Stojanovich

    Stress and autoimmunity

    Autoimmun Rev

    (2010)
  • J. Sands et al.

    Geoepidemiology and autoimmune manifestations of lymphoproliferative disorders

    Autoimmun Rev

    (2010)
  • M. Segelmark et al.

    Autoimmune kidney diseases

    Autoimmun Rev

    (2010)
  • G.J. Tobon et al.

    The environment, geo-epidemiology, and autoimmune disease: rheumatoid arthritis

    Autoimmun Rev

    (2010)
  • Cited by (77)

    • Vitamin D

      2023, Feldman and Pike's Vitamin D: Volume One: Biochemistry, Physiology and Diagnostics
    • Vitamin D, Pregnancy, and Autoimmunity: An Ongoing Mystery

      2019, Mosaic of Autoimmunity: The Novel Factors of Autoimmune Diseases
    View all citing articles on Scopus
    1

    Both authors have equally contributed to this manuscript.

    View full text